ATE398459T1 - Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen - Google Patents

Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen

Info

Publication number
ATE398459T1
ATE398459T1 AT97924210T AT97924210T ATE398459T1 AT E398459 T1 ATE398459 T1 AT E398459T1 AT 97924210 T AT97924210 T AT 97924210T AT 97924210 T AT97924210 T AT 97924210T AT E398459 T1 ATE398459 T1 AT E398459T1
Authority
AT
Austria
Prior art keywords
naip
prevention
iap
treatment
neuronal diseases
Prior art date
Application number
AT97924210T
Other languages
English (en)
Inventor
Robert Korneluk
Alexander MACKENZIE
George Robertson
D Xu
S Krocker
Original Assignee
Univ Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ottawa filed Critical Univ Ottawa
Application granted granted Critical
Publication of ATE398459T1 publication Critical patent/ATE398459T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97924210T 1996-04-26 1997-04-25 Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen ATE398459T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1735496P 1996-04-26 1996-04-26
US3059096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
ATE398459T1 true ATE398459T1 (de) 2008-07-15

Family

ID=26689763

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97924210T ATE398459T1 (de) 1996-04-26 1997-04-25 Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen

Country Status (6)

Country Link
US (3) US6159948A (de)
EP (1) EP0840617B1 (de)
AT (1) ATE398459T1 (de)
CA (1) CA2222453C (de)
DE (1) DE69738776D1 (de)
WO (1) WO1997040847A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087173A (en) * 1999-09-09 2000-07-11 Isis Pharmaceuticals Inc. Antisense modulation of X-linked inhibitor of apoptosis expression
US6511828B1 (en) 1996-05-31 2003-01-28 Arch Development Corporation Human and drosophila inhibitors of apoptosis proteins (IAPs)
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
ES2281135T3 (es) * 1997-08-14 2007-09-16 Institut Pasteur Proteinas hibridas de un toxoide tetanico que migran de forma retrograda y transinaptica al snc.
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO1999062943A2 (en) * 1998-06-02 1999-12-09 Millenium Pharmaceuticals, Inc. Novel molecules of the aip-related protein family and uses thereof
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US9192780B2 (en) * 1998-11-30 2015-11-24 L'oreal Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders
US6887260B1 (en) 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6283956B1 (en) 1998-11-30 2001-09-04 David H. McDaniels Reduction, elimination, or stimulation of hair growth
US20060212025A1 (en) 1998-11-30 2006-09-21 Light Bioscience, Llc Method and apparatus for acne treatment
JP2004531731A (ja) * 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
US6573300B2 (en) 2001-08-24 2003-06-03 China Medical College Hospital Hydroxyurea treatment for spinal muscular atrophy
EP1539189A4 (de) * 2002-03-25 2007-05-09 Univ Boston Verfahren zur verwendung von anti-apoptose-faktoren in der genexpression
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
JP2006522660A (ja) * 2003-04-10 2006-10-05 ライト バイオサイエンス，エルエルシー 細胞増殖及び遺伝子発現を調節するためのフォトモジュレーション方法及び装置
ES2572976T3 (es) 2003-07-31 2016-06-03 Gentlewaves Llc Sistema y método para el tratamiento fotodinámico de la piel
WO2006047250A2 (en) * 2004-10-22 2006-05-04 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
CA2628108C (en) 2005-11-10 2020-01-07 Certara Usa, Inc. Method and apparatus for computer modeling the human brain for predicting drug effects
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
EP2068866A4 (de) 2006-07-24 2010-04-07 Biogen Idec Inc Verfahren zur förderung von myelinisierung, neuronalem überleben und oligodendrozytendifferenzierung mittels verabreichung von sp35- bzw. trka-antagonisten
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3562528B2 (ja) * 1992-09-14 2004-09-08 ザ ジェネラル ホスピタル コーポレイション Ｉｋａｒｏｓ：ｔ細胞経路調節遺伝子
DE69534629D1 (de) * 1994-01-18 2005-12-29 Scripps Research Inst Derivate von zinkfingerproteinen und methoden
US6020127A (en) * 1994-10-18 2000-02-01 The University Of Ottawa Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy
US6156535A (en) * 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AU6692996A (en) 1995-08-08 1997-03-05 Tularik Inc. Inhibitors of apoptosis
US6187557B1 (en) 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
GB9601108D0 (en) * 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)

Also Published As

Publication number Publication date
US6709866B2 (en) 2004-03-23
WO1997040847A1 (en) 1997-11-06
DE69738776D1 (de) 2008-07-31
US6159948A (en) 2000-12-12
EP0840617A1 (de) 1998-05-13
CA2222453A1 (en) 1997-11-06
EP0840617B1 (de) 2008-06-18
US20010021699A1 (en) 2001-09-13
CA2222453C (en) 2009-06-30

Similar Documents

Publication Publication Date Title
ATE398459T1 (de) Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
DE59914996D1 (en) Heterocyclisch substituierte amide als calpainhemmer
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
DE60138019D1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
AU2002366641A1 (en) Methods for inhibiting ocular processes
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE69224069D1 (de) Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DE69413789D1 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
SE9604348D0 (sv) Användning av hydroxyguanidiner
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties